3064 completed, 712 unknown, 693 terminated, 508 recruiting. 5701 Phase 2, 1163 Phase 1, 608 Phase 3.
Follow Vascular Diseases: new trials by email Literature Review of Vascular Diseases trials Research Report on Vascular Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance Vigabatrin Pill, Placebo oral tablet - Hyperinsulinism, Insulin Resistance | Phase 2 | Withdrawn | University of Arizona | 2030-04-15 | 2025-07-30 | |
| FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease FGF-1, Placebo - Peripheral Arterial Disease, Stenosis | Phase 1 / Phase 2 | Not yet recruiting | Venturis Therapeutics, Inc. | 24 | 2028-10-15 | 2026-08-19 |
| Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose, Human Recombinant Fibroblast Growth Factor-1 (FGF1-141) - high dose, Placebo - Coronary Disease, Coronary Heart Disease | Phase 2 | Not yet recruiting | Venturis Therapeutics, Inc. | 150 | 2027-09-01 | 2026-08-19 |
| Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulopathy • Sivelestat intravenous infusion, NaCl intravenous infusion - Septic Shock, Coagulopathy | Phase 2 | Not yet recruiting | University Hospital, Strasbourg, France | 120 | 2027-08-01 | 2026-08-20 |
| Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 80 | 2027-05-22 | 2026-10-23 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Intranasal Stem Cells to Treat Perinatal Brain Injury to Combat Cerebral Palsy MSC, marrow, Placebo - Perinatal Arterial Ischemic Stroke, Perinatal Asphyxia | Phase 2 / Phase 3 | Not yet recruiting | UMC Utrecht | 162 | 2027-04-01 | 2026-09-21 |
| Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy ceftazidime, ciprofloxacin, Standard-of-Care Antibiotic Strategy - Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | Zealand University Hospital | 150 | 2027-03-01 | 2026-09-25 |
| MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy - Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | University of Arkansas | 50 | 2027-03-01 | 2026-09-02 |
| A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus) Glycerol Tributyrate - MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus) | Phase 1 / Phase 2 | Not yet recruiting | George Washington University | 24 | 2027-03-01 | 2026-10-05 |
| Reducing Arterial Inflammation Using Eplerenone and Statins in HIV Eplerenone, Placebo - HIV (Human Immunodeficiency Virus), Cardiovascular Diseases (CVD) | Phase 2 / Phase 3 | Not yet recruiting | Massachusetts General Hospital | 124 | 2027-03-01 | 2026-10-23 |
| Teclistamab In Waldenstrom's Macroglobulinemia Teclistamab - Waldenstrom's Macroglobulinemia | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 24 | 2027-02-19 | 2026-09-01 |
| Regenerative Medicine for Joint Hypermobility and Instability Dextrose 20% Prolotherapy, Autologous Platelet-Rich Plasma, Doxycycline Hyclate Injectable (Investigational) - Ehlers-Danlos Syndrome Hypermobility Type (hEDS), Ehlers-Danlos Syndrome (EDS) | Phase 1 / Phase 2 | Not yet recruiting | Manhattan Pain Medicine, PLLC | 100 | 2027-01-15 | 2026-10-06 |
| Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization rhTPO prophylaxis plus EAP stem-cell mobilization - Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 70 | 2027-01-01 | 2026-09-30 |
| Ventricular mTOR Inhibition to Prevent Hydrocephalus After Brain Hemorrhage Sirolimus (Rapamune®) - Post-hemorrhagic Hydrocephalus (PHH) | Phase 1 / Phase 2 | Not yet recruiting | Massachusetts General Hospital | 15 | 2027-01-01 | 2026-06-25 |
| Relaxin Therapy for Atrial Fibrillation Relaxin, Placebo - Atrial Fibrillation (AF), Arrhythmia | Phase 1 / Phase 2 | Not yet recruiting | Deeptankar DeMazumder | 208 | 2027-01-01 | 2026-01-22 |
| Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells Isatuximab, VRD - Multiple Myeloma | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 15 | 2027-01-01 | 2026-10-02 |
| CC-101 (f/k/a NR1) Neural Stem Cell Transplantation for Adults With Chronic Ischemic Stroke CC-101 (f/k/a NR1) Intracerebral Transplantation, Tacrolimus, Sham Surgical Control - Chronic Ischemic Stroke | Phase 2 | Not yet recruiting | Clarion Cells, Inc. | 36 | 2027-01-01 | 2026-07-17 |
| Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI Empagliflozin (SGLT2i), dapagliflozin, Standard medical treatment - No Reflow Phenomenon, Reperfusion Injuries, Myocardial | Phase 2 | Not yet recruiting | Al-Azhar University | 100 | 2027-01-01 | 2026-10-27 |
| Human Umbilical Cord Mesenchymal Stem Cell Therapy (19#iSCLife®-CI) for Cerebral Infarction Patients in Convalescent Period. Allogeneic umbilical cord mesenchymal stem cell, Aspirin Enteric-coated Tablets & Atorvastatin Calcium - Cerebral Infarction | Phase 1 / Phase 2 | Suspended | Sclnow Biotechnology Co., Ltd. | 40 | 2026-12-31 | 2026-04-23 |
Showing 20 of 5701. Sign in to see all of them.
Multiple Myeloma (1581) · Stroke (540) · Hypertension (419) · Ischemic Stroke (370) · Coronary Artery Disease (299) · Neoplasms, Plasma Cell (276) · Lymphoma (253) · Waldenstrom Macroglobulinemia (253) · Lymphoma, Non-Hodgkin (252) · Leukemia, Lymphocytic, Chronic, B-Cell (239) · Recurrence (214) · Lymphoma, Follicular (206) · Lymphoma, B-Cell, Marginal Zone (196) · Hodgkin Disease (194) · Lymphoma, Mantle-Cell (180)
Cardiovascular Diseases (5537) · Immune System Diseases (1980) · Hemic and Lymphatic Diseases (1941) · Hematologic Diseases (1865) · Hemorrhagic Disorders (1855) · Pathological Conditions, Signs and Symptoms (1839) · Hemostatic Disorders (1822) · Neoplasms by Histologic Type (1810) · Immunoproliferative Disorders (1779) · Lymphoproliferative Disorders (1779) · Blood Protein Disorders (1765) · Neoplasms (1764) · Paraproteinemias (1758) · Neoplasms, Plasma Cell (1495)
Dexamethasone (519) · Bortezomib (271) · Lenalidomide (265) · Cyclophosphamide (251) · Melphalan (174) · Calcium Dobesilate (168) · daratumumab (130) · carfilzomib (113) · pomalidomide (111) · Rituximab (107) · Sodium Chloride (97) · Peripheral Blood Stem Cell Transplantation (92) · fludarabine phosphate (92) · Filgrastim (82) · Aspirin (81)
National Cancer Institute (NCI) (111) · Mayo Clinic (79) · Novartis Pharmaceuticals (62) · Fred Hutchinson Cancer Center (56) · M.D. Anderson Cancer Center (54) · Memorial Sloan Kettering Cancer Center (48) · National Heart, Lung, and Blood Institute (NHLBI) (48) · GlaxoSmithKline (43) · University of Arkansas (37) · Bayer (35) · Dana-Farber Cancer Institute (33) · Massachusetts General Hospital (29) · Assistance Publique - Hôpitaux de Paris (28) · Beijing Tiantan Hospital (26) · Boehringer Ingelheim (26)
United States (2811) · China (484) · Germany (463) · Canada (456) · United Kingdom (399) · France (358) · Spain (286) · Italy (278) · Netherlands (234) · Australia (216) · South Korea (180) · Poland (177) · Belgium (165) · Denmark (151) · Israel (146)
PMID 37870112, PMID 33175411, PMID 32499241, PMID 33357481, PMID 42573020, PMID 36326435, PMID 30957581, PMID 24107737, PMID 27657681, PMID 35244208, PMID 35285981, PMID 35549810, PMID 35802393, PMID 20185783, PMID 21762873, PMID 22163120, PMID 22496083, PMID 25671797, PMID 25726502, PMID 31221778, PMID 33027067, PMID 33086312, PMID 33107592, PMID 33337539, PMID 33502773, PMID 34182226, PMID 34398557, PMID 34906976, PMID 35526057, PMID 36289001, PMID 36408587, PMID 37740111, PMID 37934000, PMID 38189593, PMID 40156952, PMID 41114449, PMID 16574919, PMID 16990385, PMID 17090774, PMID 17825712, PMID 18296121, PMID 18536865, PMID 19118718, PMID 19179301, PMID 19233036, PMID 19387663, PMID 19834014, PMID 20651267, PMID 20661232, PMID 21079055
2023 (53), P30CA015083 (38), U10CA180820 (38), 2017 (37), 2018 (29), 2015 (27), 2016 (27), 2019 (27), 2014 (25), 2025 (24), P30CA015704 (24), 2008 (22), U24CA196172 (20), 2009 (16), 2005 (14)